Plateauing on Wegovy: what's actually going on

It's week ten and the number on the scale hasn't moved in a fortnight

That's the situation most people describe. The first month on Wegovy produced a noticeable drop. Then, somewhere between weeks eight and sixteen, the loss slowed to almost nothing. The instinct is to blame the medicine, or yourself. Both are usually wrong.

What's happening is largely metabolic. As body weight falls, the body reduces its resting energy expenditure, it becomes more efficient at running on fewer calories. This is sometimes called adaptive thermogenesis, and it's a well-documented response to sustained weight loss, not specific to GLP-1 medicines. Your body is defending a set point it hasn't quite let go of yet. Wegovy continues to work on appetite and gastric emptying throughout this period, and if you want to understand what's driving this in more detail, our guide to the Wegovy plateau explains the underlying biology and what typically happens next.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks. Average weight reduction was around 15% at the 2.4mg maintenance dose, but that average masks the shape of the curve. Loss was fastest in the first three months, then slowed considerably. Participants who appeared to plateau mid-trial often continued losing weight when measured at the 68-week endpoint. The timeline is longer than most people expect.

One misconception worth naming gently: many people arrive at a plateau convinced they need to halve their dose or come off the medicine entirely. The opposite is often clinically appropriate. Staying on the current dose while reviewing lifestyle factors, or discussing a titration step with a prescriber, is usually a more productive path.

The factors a prescriber actually looks at when progress stalls

A plateau isn't one thing. A clinician reviewing it will consider several distinct possibilities, because the right response depends on the cause.

First, dose. Wegovy's schedule runs from 0.25mg to the standard 2.4mg maintenance dose, titrated roughly every four weeks by the prescriber. If someone has stabilised at 1.7mg and the appetite suppression is wearing off between doses, a move to 2.4mg may be appropriate. The MHRA approved a dedicated 7.2mg single-dose pen in April 2026, providing an additional step for adults with a BMI of 30 or above where a prescriber judges it suitable. Specific dose availability is confirmed through a clinical consultation rather than assumed.

Second, the lifestyle side. Semaglutide reduces appetite substantially, but it doesn't override a significant caloric surplus or extended physical inactivity. Protein intake tends to fall when appetite drops, and inadequate protein during weight loss accelerates the loss of lean mass, which itself lowers metabolic rate further. A prescriber or dietitian reviewing food quality (not just quantity) often finds a practical lever here.

Third, other medicines and conditions. Some medications affect weight independently. Certain health conditions do too. A full clinical picture review matters. The NHS semaglutide page lists the interactions and conditions that require monitoring during treatment.

Fourth, time. Genuinely, this is underrated. Plateaus that feel permanent at week twelve have resolved by week twenty-four for many people without any change to treatment at all. Your prescriber can help you read whether yours looks like a pause or a stopping point.

Practical things that can genuinely help

There's no shortage of advice online about breaking a weight-loss plateau, and some of it is unhelpful. A few things have reasonable clinical grounding.

Protein adequacy matters more than most people realise on a GLP-1 medicine. When appetite falls sharply, food volume drops, and if protein drops with it, muscle mass follows. Aiming for adequate protein across fewer, smaller meals helps preserve the lean tissue that keeps metabolism higher. The NHS Better Health guidance offers a practical starting framework for eating well during weight management.

Resistance-based activity is worth mentioning in the same breath. Cardiovascular exercise burns calories; resistance work builds and preserves the muscle that keeps your metabolic rate from falling as fast. Neither is a requirement, and a clinical team will never prescribe exercise in a one-size way, but the combination is consistently supported by the evidence.

Sleep and stress are real factors, not lifestyle-magazine filler. Cortisol (a stress hormone) directly affects fat storage patterns and hunger signalling. Poor sleep is independently associated with reduced weight-loss response in studies of obesity treatment. These aren't things to feel guilty about; they're clinical variables worth raising.

If you want to understand more about how long it typically takes for Wegovy to show results, the timeline for Wegovy to work covers what the trial data actually shows, week by week. And for a fuller picture of the medicine itself, the Wegovy overview sets out how it works and who it's licensed for.

Anyone who has plateaued on Wegovy and is wondering whether their current provider is giving them adequate clinical support can read about where to get Wegovy on a private prescription in the UK. Cost context, including what a legitimate private prescription actually includes beyond the medicine itself, is covered on our weight-loss treatment options page.

The prescribers at our clinical team review plateau situations regularly, and our dedicated page on hitting a plateau on Wegovy covers the clinical options available when progress stalls. If your current treatment feels stuck and you haven't had a clinical review recently, that's the right starting point, not a change to your own dose, and not stopping the medicine unilaterally.